1,719 research outputs found
Cancer prevention and vitamin K antagonists: An overview
No full textThe relation of cancer to thromboembolism has been described since the mid 1800s. Different studies in animal and in vitro models have confirmed the link between the haemostatic system and both tumor stroma formation and metastasis. Although the mechanisms of warfarin effects on cancer are not elucidated, but are based on hypothesis, various studies have reported interesting results in this setting. But does warfarin added to recommended anti-tumour therapy improve survival of cancer patients? For the time being it is difficult to answer this question. Data from the literature are few and sometimes contradictory. Trials are characterized by important differences in studied cohorts, histological types of cancers evaluated, and in the treatment protocols. Most studies show that there is benefit from the addition of warfarin to chemotherapy in the tumour development, expansion and on the patient survival, especially in particular types of cancers. These data, although fascinating, do not rationalize the use of anticoagulation in the routine prophylaxis of cancer, however, they call for efforts in preparing large scale randomized trials to elucidate the effect of anticoagulation in the setting of neoplastic disease
Long-term use of vitamin K antagonists and incidence of cancer: a population-based study
No full textWhether long-term use of vitamin K antagonists (VKAs) might affect the incidence of cancer is a longstanding hypothesis. We conducted a population-based study including all cancer- and thromboembolism-free patients of our health area; study groups were defined according to chronic anticoagulant use to VKA-exposed and control groups. Cancer incidence and cancer-related and overall mortality was assessed in both groups. 76 008 patients (3231 VKA-exposed and 72 777 control subjects) were followed-up for 8.2 (± 3.2) years. After adjusting for age, sex, and time-to-event, the hazard ratio of newly diagnosed cancer in the exposed group was 0.88 (95% confidence interval [95% CI] 0.80-0.98; P < .015). VKA-exposed patients were less likely to develop prostate cancer, 0.69 (95% CI 0.50-0.97; P = .008). The adjusted hazard ratio for cancer-related and overall mortality was 1.07 (95% CI 0.92-1.24) and 1.12 (95% CI 1.05-1.19), respectively. These results support the hypothesis that anticoagulation might have a protective effect on cancer development, especially prostate cancer
Catheter-related atrial thrombosis in a patient with recent cerebral haemorrhage: to treat or not to treat?
No full textTreatment options in fibromuscular dysplasia of the renal artery: when percutaneous transluminal angioplasty is at high risk?
No full textAntiplatelets treatment in atherosclerotic renal artery stenosis: need of consensus-based recommendations.
No full textNoSAS score associated with arterial stiffness in a large cohort of healthy individuals.
No full textWe read with interest Helena Marti-Soler and colleagues' Article1 in the Lancet Respiratory Medicine on their proposed clinical algorithm (NoSAS), which showed good sensitivity for detecting individuals at risk of sleep-disordered breathing with greater accuracy than other validated questionnaires. This algorithm could be potentially useful for screening purposes in large cohorts for whom polysomnography is too expensive and time consuming
Pelvic-ureteric junction obstruction and hypertension with target organ damage: A case report and review of the literature.
No full textTrattamento Medico o endovascolare nell'ipertensione nefrovascolare aterosclerotica? Risultati di una Meta-analisi degli studi clinici randomizzati di confronto.
No full textRIC-HSCT for MF/SS
No full textAdvanced-stage mycosis fungoides and Sezary syndrome (MF/SS) have a poor prognosis. Allogeneic hematopoietic stem cell transplantation (HSCT), particularly using a reduced-intensity conditioning (RIC) regimen, is a promising treatment for advanced-stage MF/SS. We performed RIC-HSCT in nine patients with advanced MF/SS. With a median follow-up period of 954days after HSCT, the estimated 3-year overall survival was 85.7% (95% confidence interval, 33.4-97.9%) with no non-relapse mortality. Five patients relapsed after RIC-HSCT; however, in four patients whose relapse was detected only from the skin, persistent complete response was achieved in one patient, and the disease was manageable in other three patients by the tapering of immunosuppressants and donor lymphocyte infusion, suggesting that graft-versus-lymphoma effect and "down-staging" effect from advanced stage to early stage by HSCT improve the prognosis of advanced-stage MF/SS. These results suggest that RIC-HSCT is an effective treatment for advanced MF/SS
- …
